factuality_value
stringclasses 7
values | predicat@xml:space
stringclasses 1
value | predicat@charOffset
stringlengths 3
9
| predicat@headOffset
stringlengths 3
9
| predicat@id
stringclasses 206
values | predicat@text
stringlengths 2
124
| predicat@type
stringclasses 29
values | predicat@charOffsetMin
int64 0
3.96k
| predicat@charOffsetMax
int64 6
3.97k
| subject@xml:space
stringclasses 1
value | subject@charOffset
stringlengths 3
9
| subject@headOffset
stringlengths 3
9
| subject@id
stringclasses 197
values | subject@text
stringlengths 2
49
| subject@type
stringclasses 72
values | subject@charOffsetMin
int64 0
3.98k
| subject@charOffsetMax
int64 3
4k
| object@xml:space
stringclasses 1
value | object@charOffset
stringlengths 3
9
| object@headOffset
stringlengths 3
9
| object@id
stringclasses 198
values | object@text
stringlengths 2
53
| object@type
stringclasses 73
values | object@charOffsetMin
int64 0
3.93k
| object@charOffsetMax
int64 4
3.94k
| id
stringclasses 58
values | raw_sent_text
stringlengths 20
749
| sent_charOffset
stringlengths 4
9
| sent_charOffsetMin
int64 0
3.88k
| sent_charOffsetMax
int64 26
4.2k
| formated_sentence
stringlengths 34
768
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fact | preserve | 168-288 | 201-211 | T18 | aldosterone are not always fully suppressed during chronic angiotensin converting enzyme (ACE) inhibitor treatment | ISA | 168 | 288 | preserve | 143-157 | 143-154 | T11 | Angiotensin II | AminoAcidPeptideOrProtein | 143 | 157 | preserve | 279-288 | 279-288 | T17 | treatment | TherapeuticOrPreventiveProcedure | 279 | 288 | A11 | OBJECTIVE: Angiotensin II (AII) and aldosterone are not always fully suppressed during chronic angiotensin converting enzyme (ACE) inhibitor treatment. | 132-289 | 132 | 289 | OBJECTIVE: @SUBJECT$ (AII) and @PREDICAT$ @OBJECT$ . |
Fact | preserve | 1785-1789 | 1785-1789 | T118 | with | PART_OF | 1,785 | 1,789 | preserve | 1802-1805 | 1802-1805 | T112 | ACE | AminoAcidPeptideOrProtein | 1,802 | 1,805 | preserve | 1776-1784 | 1776-1784 | T110 | patients | PatientOrDisabledGroup | 1,776 | 1,784 | A12 | In patients with high plasma ACE concentrations, non-compliance should be considered along with inadequate dose titration. | 1773-1907 | 1,773 | 1,907 | In @OBJECT$ @PREDICAT$ high plasma @SUBJECT$ concentrations, non-compliance should be considered along with inadequate dose titration. |
Fact | preserve | 102-111 | 102-111 | T10 | treatment | TREATS | 102 | 111 | preserve | 88-101 | 92-101 | T6 | ACE inhibitor | PharmacologicSubstance | 88 | 101 | preserve | 115-130 | 123-130 | T8 | cardiac failure | DiseaseOrSyndrome | 115 | 130 | A16 | How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? | 0-131 | 0 | 131 | How often are angiotensin II and aldosterone concentrations raised during chronic @SUBJECT$ @PREDICAT$ in @OBJECT$ ? |
Fact | preserve | 2242-2249 | 2242-2249 | T151 | treated | TREATS | 2,242 | 2,249 | preserve | 2258-2271 | 2262-2271 | T148 | ACE inhibitor | PharmacologicSubstance | 2,258 | 2,271 | preserve | 2214-2227 | 2220-2227 | T146 | heart failure | DiseaseOrSyndrome | 2,214 | 2,227 | A17 | It is important to establish the cause of detectable or increased AII concentrations in a heart failure patient treated with an ACE inhibitor. | 2118-2272 | 2,118 | 2,272 | It is important to establish the cause of detectable or increased AII concentrations in a @OBJECT$ patient @PREDICAT$ with an @SUBJECT$ . |
Fact | preserve | 2093-2097 | 2093-2097 | T140 | than | compared_with | 2,093 | 2,097 | preserve | 2035-2046 | 2035-2046 | T134 | aldosterone | Hormone | 2,035 | 2,046 | preserve | 2098-2101 | 2098-2101 | T138 | AII | AminoAcidPeptideOrProtein | 2,098 | 2,101 | A18 | Raised aldosterone concentrations appear to be more common than AII "reactivation". | 2028-2117 | 2,028 | 2,117 | Raised @SUBJECT$ concentrations appear to be more common @PREDICAT$ @OBJECT$ "reactivation". |
Fact | preserve | 1920-1924 | 1920-1924 | T130 | with | PART_OF | 1,920 | 1,924 | preserve | 1936-1939 | 1936-1939 | T122 | ACE | AminoAcidPeptideOrProtein | 1,936 | 1,939 | preserve | 1911-1919 | 1911-1919 | T119 | patients | PatientOrDisabledGroup | 1,911 | 1,919 | A19 | In patients with low plasma ACE and high AII concentrations, non-ACE mediated production of AII may be operative. | 1908-2027 | 1,908 | 2,027 | In @OBJECT$ @PREDICAT$ low plasma @SUBJECT$ and high AII concentrations, non-ACE mediated production of AII may be operative. |
Fact | preserve | 792-823 | 814-823 | T53 | ACE inhibitors (enalapril | ISA | 792 | 823 | preserve | 825-835 | 825-835 | T49 | lisinopril | AminoAcidPeptideOrProtein | 825 | 835 | preserve | 792-806 | 796-806 | T47 | ACE inhibitors | PharmacologicSubstance | 792 | 806 | A20 | A representative range of ACE inhibitors (enalapril, lisinopril, captopril, perindopril, and fosinopril) was examined. | 766-890 | 766 | 890 | A representative range of @OBJECT$ @PREDICAT$ , @SUBJECT$ , captopril, perindopril, and fosinopril) was examined. |
Fact | preserve | 1284-1294 | 1284-1294 | T84 | correlated | COEXISTS_WITH | 1,284 | 1,294 | preserve | 1246-1249 | 1246-1249 | T78 | AII | AminoAcidPeptideOrProtein | 1,246 | 1,249 | preserve | 1318-1321 | 1318-1321 | T80 | ACE | AminoAcidPeptideOrProtein | 1,318 | 1,321 | A21 | AII concentrations were significantly correlated (p < 0.001) with ACE but not with aldosterone concentrations. | 1246-1362 | 1,246 | 1,362 | @SUBJECT$ concentrations were significantly @PREDICAT$ (p < 0.001) with @OBJECT$ but not with aldosterone concentrations. |
Fact | preserve | 88-111 | 102-111 | T9 | ACE inhibitor treatment | USES | 88 | 111 | preserve | 102-111 | 102-111 | T7 | treatment | TherapeuticOrPreventiveProcedure | 102 | 111 | preserve | 88-101 | 92-101 | T6 | ACE inhibitor | PharmacologicSubstance | 88 | 101 | A22 | How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? | 0-131 | 0 | 131 | How often are angiotensin II and aldosterone concentrations raised during chronic @OBJECT$ @PREDICAT$ @SUBJECT$ in cardiac failure? |
Fact | preserve | 2242-2249 | 2242-2249 | T151 | treated | TREATS | 2,242 | 2,249 | preserve | 2258-2271 | 2262-2271 | T148 | ACE inhibitor | PharmacologicSubstance | 2,258 | 2,271 | preserve | 2234-2241 | 2234-2241 | T147 | patient | PatientOrDisabledGroup | 2,234 | 2,241 | A23 | It is important to establish the cause of detectable or increased AII concentrations in a heart failure patient treated with an ACE inhibitor. | 2118-2272 | 2,118 | 2,272 | It is important to establish the cause of detectable or increased AII concentrations in a heart failure @OBJECT$ @PREDICAT$ with an @SUBJECT$ . |
Fact | preserve | 168-288 | 201-211 | T18 | aldosterone are not always fully suppressed during chronic angiotensin converting enzyme (ACE) inhibitor treatment | ISA | 168 | 288 | preserve | 168-179 | 168-179 | T12 | aldosterone | Hormone | 168 | 179 | preserve | 279-288 | 279-288 | T17 | treatment | TherapeuticOrPreventiveProcedure | 279 | 288 | A24 | OBJECTIVE: Angiotensin II (AII) and aldosterone are not always fully suppressed during chronic angiotensin converting enzyme (ACE) inhibitor treatment. | 132-289 | 132 | 289 | OBJECTIVE: Angiotensin II (AII) and @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 2214-2241 | 2234-2241 | T149 | heart failure patient | PROCESS_OF | 2,214 | 2,241 | preserve | 2214-2227 | 2220-2227 | T146 | heart failure | DiseaseOrSyndrome | 2,214 | 2,227 | preserve | 2234-2241 | 2234-2241 | T147 | patient | PatientOrDisabledGroup | 2,234 | 2,241 | A25 | It is important to establish the cause of detectable or increased AII concentrations in a heart failure patient treated with an ACE inhibitor. | 2118-2272 | 2,118 | 2,272 | It is important to establish the cause of detectable or increased AII concentrations in a @SUBJECT$ @PREDICAT$ @OBJECT$ treated with an ACE inhibitor. |
Fact | preserve | 792-823 | 814-823 | T53 | ACE inhibitors (enalapril | ISA | 792 | 823 | preserve | 848-859 | 848-859 | T51 | perindopril | OrganicChemical | 848 | 859 | preserve | 792-806 | 796-806 | T47 | ACE inhibitors | PharmacologicSubstance | 792 | 806 | A27 | A representative range of ACE inhibitors (enalapril, lisinopril, captopril, perindopril, and fosinopril) was examined. | 766-890 | 766 | 890 | A representative range of @OBJECT$ @PREDICAT$ , lisinopril, captopril, @SUBJECT$ , and fosinopril) was examined. |
Fact | preserve | 233-288 | 279-288 | T20 | angiotensin converting enzyme (ACE) inhibitor treatment | USES | 233 | 288 | preserve | 279-288 | 279-288 | T17 | treatment | TherapeuticOrPreventiveProcedure | 279 | 288 | preserve | 233-278 | 269-278 | T16 | angiotensin converting enzyme (ACE) inhibitor | PharmacologicSubstance | 233 | 278 | A28 | OBJECTIVE: Angiotensin II (AII) and aldosterone are not always fully suppressed during chronic angiotensin converting enzyme (ACE) inhibitor treatment. | 132-289 | 132 | 289 | OBJECTIVE: Angiotensin II (AII) and aldosterone are not always fully suppressed during chronic @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 1929-1939 | 1936-1939 | T129 | plasma ACE | LOCATION_OF | 1,929 | 1,939 | preserve | 1929-1935 | 1929-1935 | T121 | plasma | BodySubstance | 1,929 | 1,935 | preserve | 1936-1939 | 1936-1939 | T122 | ACE | AminoAcidPeptideOrProtein | 1,936 | 1,939 | A29 | In patients with low plasma ACE and high AII concentrations, non-ACE mediated production of AII may be operative. | 1908-2027 | 1,908 | 2,027 | In patients with low @SUBJECT$ @PREDICAT$ @OBJECT$ and high AII concentrations, non-ACE mediated production of AII may be operative. |
Fact | preserve | 1813-1820 | 1813-1820 | T117 | therapy | TREATS | 1,813 | 1,820 | preserve | 1771-1782 | 1771-1782 | T102 | Naratriptan | OrganicChemical | 1,771 | 1,782 | preserve | 1831-1839 | 1831-1839 | T108 | migraine | DiseaseOrSyndrome | 1,831 | 1,839 | A1 | CONCLUSIONS: Naratriptan is a promising new oral therapy for acute migraine; it may successfully treat patients who poorly tolerate other triptan therapies or have longer duration migraine headaches. | 1758-1975 | 1,758 | 1,975 | CONCLUSIONS: @SUBJECT$ is a promising new oral @PREDICAT$ for acute @OBJECT$ ; it may successfully treat patients who poorly tolerate other triptan therapies or have longer duration migraine headaches. |
Fact | preserve | 1908-1925 | 1916-1925 | T115 | triptan therapies | ISA | 1,908 | 1,925 | preserve | 1908-1915 | 1908-1915 | T111 | triptan | OrganicChemical | 1,908 | 1,915 | preserve | 1916-1925 | 1916-1925 | T112 | therapies | TherapeuticOrPreventiveProcedure | 1,916 | 1,925 | A2 | CONCLUSIONS: Naratriptan is a promising new oral therapy for acute migraine; it may successfully treat patients who poorly tolerate other triptan therapies or have longer duration migraine headaches. | 1758-1975 | 1,758 | 1,975 | CONCLUSIONS: Naratriptan is a promising new oral therapy for acute migraine; it may successfully treat patients who poorly tolerate other @SUBJECT$ @PREDICAT$ @OBJECT$ or have longer duration migraine headaches. |
Fact | preserve | 850-859 | 850-859 | T54 | treatment | TREATS | 850 | 859 | preserve | 925-936 | 925-936 | T49 | sumatriptan | OrganicChemical | 925 | 936 | preserve | 863-871 | 863-871 | T47 | migraine | DiseaseOrSyndrome | 863 | 871 | A3 | DATA SYNTHESIS: The treatment of migraine has been dramatically improved with the use of sumatriptan, other triptans, and serotonin-receptor subtype 1B and 1D agonists. | 830-1010 | 830 | 1,010 | DATA SYNTHESIS: The @PREDICAT$ of @OBJECT$ has been dramatically improved with the use of @SUBJECT$ , other triptans, and serotonin-receptor subtype 1B and 1D agonists. |
Fact | preserve | 1147-1217 | 1177-1185 | T67 | Naratriptan has been recently approved for acute oral migraine therapy | ISA | 1,147 | 1,217 | preserve | 1147-1158 | 1147-1158 | T61 | Naratriptan | OrganicChemical | 1,147 | 1,158 | preserve | 1210-1217 | 1210-1217 | T66 | therapy | TherapeuticOrPreventiveProcedure | 1,210 | 1,217 | A4 | Naratriptan has been recently approved for acute oral migraine therapy. | 1147-1218 | 1,147 | 1,218 | @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 1929-1933 | 1929-1933 | T119 | have | PROCESS_OF | 1,929 | 1,933 | preserve | 1950-1974 | 1965-1974 | T114 | migraine headaches | DiseaseOrSyndrome | 1,950 | 1,974 | preserve | 1867-1875 | 1867-1875 | T109 | patients | PatientOrDisabledGroup | 1,867 | 1,875 | A5 | CONCLUSIONS: Naratriptan is a promising new oral therapy for acute migraine; it may successfully treat patients who poorly tolerate other triptan therapies or have longer duration migraine headaches. | 1758-1975 | 1,758 | 1,975 | CONCLUSIONS: Naratriptan is a promising new oral therapy for acute migraine; it may successfully treat @OBJECT$ who poorly tolerate other triptan therapies or @PREDICAT$ longer duration @SUBJECT$ . |
Fact | preserve | 1258-1266 | 1258-1266 | T82 | compared | compared_with | 1,258 | 1,266 | preserve | 1246-1257 | 1246-1257 | T71 | naratriptan | OrganicChemical | 1,246 | 1,257 | preserve | 1272-1279 | 1272-1279 | T72 | placebo | MedicalDevice | 1,272 | 1,279 | A6 | In two Phase III trials of naratriptan compared with placebo, relief at four hours was obtained in 60% and 68% of patients using the 2.5-mg dose, with recurrence of headache in 24 hours in 27% and 28% of patients. | 1219-1444 | 1,219 | 1,444 | In two Phase III trials of @SUBJECT$ @PREDICAT$ with @OBJECT$ , relief at four hours was obtained in 60% and 68% of patients using the 2.5-mg dose, with recurrence of headache in 24 hours in 27% and 28% of patients. |
Fact | preserve | 850-859 | 850-859 | T54 | treatment | TREATS | 850 | 859 | preserve | 944-952 | 944-952 | T50 | triptans | OrganicChemical | 944 | 952 | preserve | 863-871 | 863-871 | T47 | migraine | DiseaseOrSyndrome | 863 | 871 | A9 | DATA SYNTHESIS: The treatment of migraine has been dramatically improved with the use of sumatriptan, other triptans, and serotonin-receptor subtype 1B and 1D agonists. | 830-1010 | 830 | 1,010 | DATA SYNTHESIS: The @PREDICAT$ of @OBJECT$ has been dramatically improved with the use of sumatriptan, other @SUBJECT$ , and serotonin-receptor subtype 1B and 1D agonists. |
Fact | preserve | 28-31 | 28-31 | T4 | for | TREATS | 28 | 31 | preserve | 0-11 | 0-11 | T1 | Naratriptan | OrganicChemical | 0 | 11 | preserve | 32-40 | 32-40 | T3 | migraine | DiseaseOrSyndrome | 32 | 40 | A13 | Naratriptan: an alternative for migraine. | 0-41 | 0 | 41 | @SUBJECT$ : an alternative @PREDICAT$ @OBJECT$ . |
Fact | preserve | 1771-1820 | 1813-1820 | T116 | Naratriptan is a promising new oral therapy | ISA | 1,771 | 1,820 | preserve | 1771-1782 | 1771-1782 | T102 | Naratriptan | OrganicChemical | 1,771 | 1,782 | preserve | 1813-1820 | 1813-1820 | T106 | therapy | TherapeuticOrPreventiveProcedure | 1,813 | 1,820 | A14 | CONCLUSIONS: Naratriptan is a promising new oral therapy for acute migraine; it may successfully treat patients who poorly tolerate other triptan therapies or have longer duration migraine headaches. | 1758-1975 | 1,758 | 1,975 | CONCLUSIONS: @SUBJECT$ @PREDICAT$ @OBJECT$ for acute migraine; it may successfully treat patients who poorly tolerate other triptan therapies or have longer duration migraine headaches. |
Fact | preserve | 1210-1217 | 1210-1217 | T68 | therapy | TREATS | 1,210 | 1,217 | preserve | 1147-1158 | 1147-1158 | T61 | Naratriptan | OrganicChemical | 1,147 | 1,158 | preserve | 1201-1209 | 1201-1209 | T65 | migraine | DiseaseOrSyndrome | 1,201 | 1,209 | A16 | Naratriptan has been recently approved for acute oral migraine therapy. | 1147-1218 | 1,147 | 1,218 | @SUBJECT$ has been recently approved for acute oral @OBJECT$ @PREDICAT$ . |
Fact | preserve | 1908-1925 | 1916-1925 | T118 | triptan therapies | USES | 1,908 | 1,925 | preserve | 1916-1925 | 1916-1925 | T112 | therapies | TherapeuticOrPreventiveProcedure | 1,916 | 1,925 | preserve | 1908-1915 | 1908-1915 | T111 | triptan | OrganicChemical | 1,908 | 1,915 | A18 | CONCLUSIONS: Naratriptan is a promising new oral therapy for acute migraine; it may successfully treat patients who poorly tolerate other triptan therapies or have longer duration migraine headaches. | 1758-1975 | 1,758 | 1,975 | CONCLUSIONS: Naratriptan is a promising new oral therapy for acute migraine; it may successfully treat patients who poorly tolerate other @OBJECT$ @PREDICAT$ @SUBJECT$ or have longer duration migraine headaches. |
Fact | preserve | 1370-1377 | 1370-1377 | T88 | treated | TREATS | 1,370 | 1,377 | preserve | 1397-1411 | 1397-1411 | T85 | beclomethasone | Hormone | 1,397 | 1,411 | preserve | 1361-1369 | 1361-1369 | T83 | patients | PatientOrDisabledGroup | 1,361 | 1,369 | A4 | PImax as an absolute value was significantly lower in steroid-dependent asthmatics than in patients treated with inhaled beclomethasone and controls (p < 0.01). | 1264-1436 | 1,264 | 1,436 | PImax as an absolute value was significantly lower in steroid-dependent asthmatics than in @OBJECT$ @PREDICAT$ with inhaled @SUBJECT$ and controls (p < 0.01). |
Fact | preserve | 643-661 | 653-661 | T44 | asthmatic patients | PROCESS_OF | 643 | 661 | preserve | 643-652 | 643-652 | T40 | asthmatic | DiseaseOrSyndrome | 643 | 652 | preserve | 653-661 | 653-661 | T41 | patients | PatientOrDisabledGroup | 653 | 661 | A7 | OBJECTIVE: We aimed to evaluate the effects of long-term moderate dose of systemic corticosteroids and high-dose inhaled beclomethasone on maximal inspiratory and expiratory pressures (PImax and PEmax, respectively) in two groups of asthmatic patients exhibiting comparable levels of hyperinflation. | 392-709 | 392 | 709 | OBJECTIVE: We aimed to evaluate the effects of long-term moderate dose of systemic corticosteroids and high-dose inhaled beclomethasone on maximal inspiratory and expiratory pressures (PImax and PEmax, respectively) in two groups of @SUBJECT$ @PREDICAT$ @OBJECT$ exhibiting comparable levels of hyperinflation. |
Fact | preserve | 104-106 | 104-106 | T7 | in | COEXISTS_WITH | 104 | 106 | preserve | 88-103 | 95-103 | T4 | muscle weakness | Finding | 88 | 103 | preserve | 107-113 | 107-113 | T5 | asthma | DiseaseOrSyndrome | 107 | 113 | A9 | Inhaled and systemic corticosteroid therapies: Do they contribute to inspiratory muscle weakness in asthma? | 0-114 | 0 | 114 | Inhaled and systemic corticosteroid therapies: Do they contribute to inspiratory @SUBJECT$ @PREDICAT$ @OBJECT$ ? |
Fact | preserve | 1664-1682 | 1674-1682 | T102 | asthmatic patients | PROCESS_OF | 1,664 | 1,682 | preserve | 1664-1673 | 1664-1673 | T100 | asthmatic | DiseaseOrSyndrome | 1,664 | 1,673 | preserve | 1674-1682 | 1674-1682 | T101 | patients | PatientOrDisabledGroup | 1,674 | 1,682 | A10 | A significant correlation was found between %PImax and hyperinflation assessed by %RV, %FRC, %FRC/TLC (p < 0.05) in all asthmatic patients. | 1532-1683 | 1,532 | 1,683 | A significant correlation was found between %PImax and hyperinflation assessed by %RV, %FRC, %FRC/TLC (p < 0.05) in all @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 21-45 | 36-45 | T6 | corticosteroid therapies | USES | 21 | 45 | preserve | 12-45 | 36-45 | T2 | systemic corticosteroid therapies | TherapeuticOrPreventiveProcedure | 12 | 45 | preserve | 21-35 | 21-35 | T1 | corticosteroid | Hormone | 21 | 35 | A11 | Inhaled and systemic corticosteroid therapies: Do they contribute to inspiratory muscle weakness in asthma? | 0-114 | 0 | 114 | Inhaled and @SUBJECT$ @OBJECT$ @PREDICAT$ : Do they contribute to inspiratory muscle weakness in asthma? |
Fact | preserve | 136-140 | 136-140 | T17 | with | PROCESS_OF | 136 | 140 | preserve | 141-147 | 141-147 | T9 | asthma | DiseaseOrSyndrome | 141 | 147 | preserve | 127-135 | 127-135 | T8 | Patients | PatientOrDisabledGroup | 127 | 135 | A13 | BACKGROUND: Patients with asthma incur the risk of steroid-induced myopathy, which is a well-known side effect of treatment with corticosteroids. | 115-266 | 115 | 266 | BACKGROUND: @OBJECT$ @PREDICAT$ @SUBJECT$ incur the risk of steroid-induced myopathy, which is a well-known side effect of treatment with corticosteroids. |
Fact | preserve | 1370-1377 | 1370-1377 | T88 | treated | TREATS | 1,370 | 1,377 | preserve | 1397-1411 | 1397-1411 | T85 | beclomethasone | Hormone | 1,397 | 1,411 | preserve | 1342-1352 | 1342-1352 | T82 | asthmatics | DiseaseOrSyndrome | 1,342 | 1,352 | A14 | PImax as an absolute value was significantly lower in steroid-dependent asthmatics than in patients treated with inhaled beclomethasone and controls (p < 0.01). | 1264-1436 | 1,264 | 1,436 | PImax as an absolute value was significantly lower in steroid-dependent @OBJECT$ than in patients @PREDICAT$ with inhaled @SUBJECT$ and controls (p < 0.01). |
Fact | preserve | 2141-2168 | 2160-2168 | T132 | inspiratory muscle function | PROCESS_OF | 2,141 | 2,168 | preserve | 2141-2152 | 2141-2152 | T127 | inspiratory | OrganOrTissueFunction | 2,141 | 2,152 | preserve | 2153-2168 | 2160-2168 | T128 | muscle function | OrganOrTissueFunction | 2,153 | 2,168 | A16 | CONCLUSIONS: We believe that hyperinflation plays a major role in inspiratory muscle dysfunction in asthma, but the finding of significantly decreased PImax values in steroid-dependent asthmatics when compared with patients on high-dose inhaled beclomethasone with a comparable level of hyperinflation points to a deleterious effect of long-term, moderate-dose systemic corticosteroid but not high-dose beclomethasone on inspiratory muscle function in asthmatics. | 1684-2183 | 1,684 | 2,183 | CONCLUSIONS: We believe that hyperinflation plays a major role in inspiratory muscle dysfunction in asthma, but the finding of significantly decreased PImax values in steroid-dependent asthmatics when compared with patients on high-dose inhaled beclomethasone with a comparable level of hyperinflation points to a deleterious effect of long-term, moderate-dose systemic corticosteroid but not high-dose beclomethasone on @SUBJECT$ @PREDICAT$ @OBJECT$ in asthmatics. |
Fact | preserve | 1034-1046 | 1034-1046 | T62 | attributable | CAUSES | 1,034 | 1,046 | preserve | 1050-1072 | 1063-1072 | T54 | occupational exposures | InjuryOrPoisoning | 1,050 | 1,072 | preserve | 1020-1026 | 1020-1026 | T53 | asthma | DiseaseOrSyndrome | 1,020 | 1,026 | A1 | The risk of asthma attributable to occupational exposures is probably underappreciated due to underreporting and to inappropriate use of narrow definitions of exposure in epidemiologic studies of attributable risk. | 1008-1241 | 1,008 | 1,241 | The risk of @OBJECT$ @PREDICAT$ to @SUBJECT$ is probably underappreciated due to underreporting and to inappropriate use of narrow definitions of exposure in epidemiologic studies of attributable risk. |
Possible | preserve | 539-543 | 539-543 | T32 | risk | PREDISPOSES | 539 | 543 | preserve | 602-613 | 602-613 | T29 | isocyanates | OrganicChemical | 602 | 613 | preserve | 547-553 | 547-553 | T27 | asthma | DiseaseOrSyndrome | 547 | 553 | A3 | Painters may have an increased risk of asthma due to exposure to a variety of agents, such as isocyanates, alkyd resins, and chromates. | 502-649 | 502 | 649 | Painters may have an increased @PREDICAT$ of @OBJECT$ due to exposure to a variety of agents, such as @SUBJECT$ , alkyd resins, and chromates. |
Possible | preserve | 539-543 | 539-543 | T32 | risk | PREDISPOSES | 539 | 543 | preserve | 639-648 | 639-648 | T31 | chromates | InorganicChemical | 639 | 648 | preserve | 547-553 | 547-553 | T27 | asthma | DiseaseOrSyndrome | 547 | 553 | A4 | Painters may have an increased risk of asthma due to exposure to a variety of agents, such as isocyanates, alkyd resins, and chromates. | 502-649 | 502 | 649 | Painters may have an increased @PREDICAT$ of @OBJECT$ due to exposure to a variety of agents, such as isocyanates, alkyd resins, and @SUBJECT$ . |
Fact | preserve | 43-45 | 43-45 | T6 | in | PROCESS_OF | 43 | 45 | preserve | 0-19 | 13-19 | T1 | Occupational asthma | DiseaseOrSyndrome | 0 | 19 | preserve | 48-61 | 54-61 | T3 | spray painter | ProfessionalOrOccupationalGroup | 48 | 61 | A5 | Occupational asthma and contact dermatitis in a spray painter after introduction of an aziridine cross-linker. | 0-117 | 0 | 117 | @SUBJECT$ and contact dermatitis @PREDICAT$ a @OBJECT$ after introduction of an aziridine cross-linker. |
Fact | preserve | 43-45 | 43-45 | T6 | in | PROCESS_OF | 43 | 45 | preserve | 24-42 | 32-42 | T2 | contact dermatitis | DiseaseOrSyndrome | 24 | 42 | preserve | 48-61 | 54-61 | T3 | spray painter | ProfessionalOrOccupationalGroup | 48 | 61 | A6 | Occupational asthma and contact dermatitis in a spray painter after introduction of an aziridine cross-linker. | 0-117 | 0 | 117 | Occupational asthma and @SUBJECT$ @PREDICAT$ a @OBJECT$ after introduction of an aziridine cross-linker. |
Fact | preserve | 208-221 | 208-221 | T18 | characterized | COEXISTS_WITH | 208 | 221 | preserve | 231-250 | 239-250 | T14 | airways obstruction | DiseaseOrSyndrome | 231 | 250 | preserve | 179-207 | 197-207 | T12 | respiratory difficulty | SignOrSymptom | 179 | 207 | A7 | A 23-year-old spray painter developed contact dermatitis and respiratory difficulty characterized by small airways obstruction shortly after the polyfunctional aziridine cross-linker CX-100 began to be used in his workplace as a paint activator. | 118-381 | 118 | 381 | A 23-year-old spray painter developed contact dermatitis and @OBJECT$ @PREDICAT$ by small @SUBJECT$ shortly after the polyfunctional aziridine cross-linker CX-100 began to be used in his workplace as a paint activator. |
Possible | preserve | 539-543 | 539-543 | T32 | risk | PREDISPOSES | 539 | 543 | preserve | 627-633 | 627-633 | T30 | resins | OrganicChemical | 627 | 633 | preserve | 547-553 | 547-553 | T27 | asthma | DiseaseOrSyndrome | 547 | 553 | A8 | Painters may have an increased risk of asthma due to exposure to a variety of agents, such as isocyanates, alkyd resins, and chromates. | 502-649 | 502 | 649 | Painters may have an increased @PREDICAT$ of @OBJECT$ due to exposure to a variety of agents, such as isocyanates, alkyd @SUBJECT$ , and chromates. |
Fact | preserve | 1494-1498 | 1494-1498 | T92 | have | PROCESS_OF | 1,494 | 1,498 | preserve | 1499-1522 | 1515-1522 | T87 | coronary artery disease | DiseaseOrSyndrome | 1,499 | 1,522 | preserve | 1448-1456 | 1448-1456 | T84 | patients | PatientOrDisabledGroup | 1,448 | 1,456 | A1 | In addition to the studies completed in patients with MI, there are ongoing studies evaluating whether or not ACE inhibitors can reduce myocardial ischemic events in patients without a prior infarction who have coronary artery disease or hypertension and preserved LV function. | 1270-1571 | 1,270 | 1,571 | In addition to the studies completed in patients with MI, there are ongoing studies evaluating whether or not ACE inhibitors can reduce myocardial ischemic events in @OBJECT$ without a prior infarction who @PREDICAT$ @SUBJECT$ or hypertension and preserved LV function. |
Fact | preserve | 1778-1782 | 1778-1782 | T108 | have | PROCESS_OF | 1,778 | 1,782 | preserve | 1783-1797 | 1786-1797 | T104 | LV dysfunction | PathologicFunction | 1,783 | 1,797 | preserve | 1758-1767 | 1758-1767 | T102 | survivors | PatientOrDisabledGroup | 1,758 | 1,767 | A2 | There is also growing evidence that concomitant therapy with a beta-blocker and an ACE inhibitor may reduce mortality rates beyond that observed with ACE inhibitors alone in survivors of MI who have LV dysfunction. | 1572-1798 | 1,572 | 1,798 | There is also growing evidence that concomitant therapy with a beta-blocker and an ACE inhibitor may reduce mortality rates beyond that observed with ACE inhibitors alone in @OBJECT$ of MI who @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 1325-1329 | 1325-1329 | T90 | with | PROCESS_OF | 1,325 | 1,329 | preserve | 1330-1332 | 1330-1332 | T78 | MI | DiseaseOrSyndrome | 1,330 | 1,332 | preserve | 1316-1324 | 1316-1324 | T77 | patients | PatientOrDisabledGroup | 1,316 | 1,324 | A3 | In addition to the studies completed in patients with MI, there are ongoing studies evaluating whether or not ACE inhibitors can reduce myocardial ischemic events in patients without a prior infarction who have coronary artery disease or hypertension and preserved LV function. | 1270-1571 | 1,270 | 1,571 | In addition to the studies completed in @OBJECT$ @PREDICAT$ @SUBJECT$ , there are ongoing studies evaluating whether or not ACE inhibitors can reduce myocardial ischemic events in patients without a prior infarction who have coronary artery disease or hypertension and preserved LV function. |
Fact | preserve | 1755-1757 | 1755-1757 | T107 | in | TREATS | 1,755 | 1,757 | preserve | 1734-1748 | 1738-1748 | T101 | ACE inhibitors | PharmacologicSubstance | 1,734 | 1,748 | preserve | 1758-1767 | 1758-1767 | T102 | survivors | PatientOrDisabledGroup | 1,758 | 1,767 | A4 | There is also growing evidence that concomitant therapy with a beta-blocker and an ACE inhibitor may reduce mortality rates beyond that observed with ACE inhibitors alone in survivors of MI who have LV dysfunction. | 1572-1798 | 1,572 | 1,798 | There is also growing evidence that concomitant therapy with a beta-blocker and an ACE inhibitor may reduce mortality rates beyond that observed with @SUBJECT$ alone @PREDICAT$ @OBJECT$ of MI who have LV dysfunction. |
Fact | preserve | 966-970 | 966-970 | T55 | with | PROCESS_OF | 966 | 970 | preserve | 971-991 | 980-991 | T50 | LV dysfunction | PathologicFunction | 971 | 991 | preserve | 957-965 | 957-965 | T49 | patients | PatientOrDisabledGroup | 957 | 965 | A5 | It appears from the findings of recent studies that the greatest benefit from beta-blocker therapy is achieved in patients who are more than 60 years of age and in patients at moderate or high risk for reinfarction and death (eg, patients with LV dysfunction or arrhythmias or both). | 709-1016 | 709 | 1,016 | It appears from the findings of recent studies that the greatest benefit from beta-blocker therapy is achieved in patients who are more than 60 years of age and in patients at moderate or high risk for reinfarction and death (eg, @OBJECT$ @PREDICAT$ @SUBJECT$ or arrhythmias or both). |
Fact | preserve | 966-970 | 966-970 | T55 | with | PROCESS_OF | 966 | 970 | preserve | 995-1006 | 995-1006 | T51 | arrhythmias | PathologicFunction | 995 | 1,006 | preserve | 957-965 | 957-965 | T49 | patients | PatientOrDisabledGroup | 957 | 965 | A7 | It appears from the findings of recent studies that the greatest benefit from beta-blocker therapy is achieved in patients who are more than 60 years of age and in patients at moderate or high risk for reinfarction and death (eg, patients with LV dysfunction or arrhythmias or both). | 709-1016 | 709 | 1,016 | It appears from the findings of recent studies that the greatest benefit from beta-blocker therapy is achieved in patients who are more than 60 years of age and in patients at moderate or high risk for reinfarction and death (eg, @OBJECT$ @PREDICAT$ LV dysfunction or @SUBJECT$ or both). |
Fact | preserve | 1062-1069 | 1062-1069 | T74 | treated | TREATS | 1,062 | 1,069 | preserve | 1075-1089 | 1079-1089 | T60 | ACE inhibitors | PharmacologicSubstance | 1,075 | 1,089 | preserve | 1042-1055 | 1048-1055 | T59 | heart failure | DiseaseOrSyndrome | 1,042 | 1,055 | A8 | Patients with class I-IV heart failure treated with ACE inhibitors have fewer recurrent infarctions, a lower incidence of severe congestive heart failure, and a reduced incidence of total cardiovascular death and sudden cardiac death. | 1017-1269 | 1,017 | 1,269 | Patients with class I-IV @OBJECT$ @PREDICAT$ with @SUBJECT$ have fewer recurrent infarctions, a lower incidence of severe congestive heart failure, and a reduced incidence of total cardiovascular death and sudden cardiac death. |
Fact | preserve | 360-364 | 360-364 | T23 | with | PROCESS_OF | 360 | 364 | preserve | 374-382 | 374-382 | T17 | symptoms | SignOrSymptom | 374 | 382 | preserve | 351-359 | 351-359 | T15 | patients | PatientOrDisabledGroup | 351 | 359 | A9 | beta-Blockers reduce cardiovascular death and reinfarction in patients with a history of myocardial infarction (MI), and angiotensin-converting enzyme (ACE) inhibitors provide an overall survival benefit in patients with signs or symptoms of left ventricular (LV) dysfunction and a history of acute MI. | 132-452 | 132 | 452 | beta-Blockers reduce cardiovascular death and reinfarction in patients with a history of myocardial infarction (MI), and angiotensin-converting enzyme (ACE) inhibitors provide an overall survival benefit in @OBJECT$ @PREDICAT$ signs or @SUBJECT$ of left ventricular (LV) dysfunction and a history of acute MI. |
Fact | preserve | 832-834 | 832-834 | T53 | in | TREATS | 832 | 834 | preserve | 812-819 | 812-819 | T40 | therapy | TherapeuticOrPreventiveProcedure | 812 | 819 | preserve | 885-893 | 885-893 | T45 | patients | PatientOrDisabledGroup | 885 | 893 | A11 | It appears from the findings of recent studies that the greatest benefit from beta-blocker therapy is achieved in patients who are more than 60 years of age and in patients at moderate or high risk for reinfarction and death (eg, patients with LV dysfunction or arrhythmias or both). | 709-1016 | 709 | 1,016 | It appears from the findings of recent studies that the greatest benefit from beta-blocker @SUBJECT$ is achieved @PREDICAT$ patients who are more than 60 years of age and in @OBJECT$ at moderate or high risk for reinfarction and death (eg, patients with LV dysfunction or arrhythmias or both). |
Fact | preserve | 832-834 | 832-834 | T53 | in | TREATS | 832 | 834 | preserve | 812-819 | 812-819 | T40 | therapy | TherapeuticOrPreventiveProcedure | 812 | 819 | preserve | 835-843 | 835-843 | T41 | patients | PatientOrDisabledGroup | 835 | 843 | A12 | It appears from the findings of recent studies that the greatest benefit from beta-blocker therapy is achieved in patients who are more than 60 years of age and in patients at moderate or high risk for reinfarction and death (eg, patients with LV dysfunction or arrhythmias or both). | 709-1016 | 709 | 1,016 | It appears from the findings of recent studies that the greatest benefit from beta-blocker @SUBJECT$ is achieved @PREDICAT$ @OBJECT$ who are more than 60 years of age and in patients at moderate or high risk for reinfarction and death (eg, patients with LV dysfunction or arrhythmias or both). |
Fact | preserve | 1628-1632 | 1628-1632 | T105 | with | USES | 1,628 | 1,632 | preserve | 1620-1627 | 1620-1627 | T97 | therapy | TherapeuticOrPreventiveProcedure | 1,620 | 1,627 | preserve | 1661-1674 | 1665-1674 | T99 | ACE inhibitor | PharmacologicSubstance | 1,661 | 1,674 | A15 | There is also growing evidence that concomitant therapy with a beta-blocker and an ACE inhibitor may reduce mortality rates beyond that observed with ACE inhibitors alone in survivors of MI who have LV dysfunction. | 1572-1798 | 1,572 | 1,798 | There is also growing evidence that concomitant @SUBJECT$ @PREDICAT$ a beta-blocker and an @OBJECT$ may reduce mortality rates beyond that observed with ACE inhibitors alone in survivors of MI who have LV dysfunction. |
Fact | preserve | 1090-1094 | 1090-1094 | T75 | have | PROCESS_OF | 1,090 | 1,094 | preserve | 1111-1122 | 1111-1122 | T63 | infarctions | PathologicFunction | 1,111 | 1,122 | preserve | 1017-1025 | 1017-1025 | T57 | Patients | PatientOrDisabledGroup | 1,017 | 1,025 | A16 | Patients with class I-IV heart failure treated with ACE inhibitors have fewer recurrent infarctions, a lower incidence of severe congestive heart failure, and a reduced incidence of total cardiovascular death and sudden cardiac death. | 1017-1269 | 1,017 | 1,269 | @OBJECT$ with class I-IV heart failure treated with ACE inhibitors @PREDICAT$ fewer recurrent @SUBJECT$ , a lower incidence of severe congestive heart failure, and a reduced incidence of total cardiovascular death and sudden cardiac death. |
Fact | preserve | 146-152 | 146-152 | T21 | reduce | DISRUPTS | 146 | 152 | preserve | 132-145 | 132-145 | T6 | beta-Blockers | PharmacologicSubstance | 132 | 145 | preserve | 168-173 | 168-173 | T7 | death | OrganismFunction | 168 | 173 | A18 | beta-Blockers reduce cardiovascular death and reinfarction in patients with a history of myocardial infarction (MI), and angiotensin-converting enzyme (ACE) inhibitors provide an overall survival benefit in patients with signs or symptoms of left ventricular (LV) dysfunction and a history of acute MI. | 132-452 | 132 | 452 | @SUBJECT$ @PREDICAT$ cardiovascular @OBJECT$ and reinfarction in patients with a history of myocardial infarction (MI), and angiotensin-converting enzyme (ACE) inhibitors provide an overall survival benefit in patients with signs or symptoms of left ventricular (LV) dysfunction and a history of acute MI. |
Fact | preserve | 360-364 | 360-364 | T23 | with | PROCESS_OF | 360 | 364 | preserve | 365-370 | 365-370 | T16 | signs | SignOrSymptom | 365 | 370 | preserve | 351-359 | 351-359 | T15 | patients | PatientOrDisabledGroup | 351 | 359 | A19 | beta-Blockers reduce cardiovascular death and reinfarction in patients with a history of myocardial infarction (MI), and angiotensin-converting enzyme (ACE) inhibitors provide an overall survival benefit in patients with signs or symptoms of left ventricular (LV) dysfunction and a history of acute MI. | 132-452 | 132 | 452 | beta-Blockers reduce cardiovascular death and reinfarction in patients with a history of myocardial infarction (MI), and angiotensin-converting enzyme (ACE) inhibitors provide an overall survival benefit in @OBJECT$ @PREDICAT$ @SUBJECT$ or symptoms of left ventricular (LV) dysfunction and a history of acute MI. |
Fact | preserve | 1026-1030 | 1026-1030 | T73 | with | PROCESS_OF | 1,026 | 1,030 | preserve | 1042-1055 | 1048-1055 | T59 | heart failure | DiseaseOrSyndrome | 1,042 | 1,055 | preserve | 1017-1025 | 1017-1025 | T57 | Patients | PatientOrDisabledGroup | 1,017 | 1,025 | A20 | Patients with class I-IV heart failure treated with ACE inhibitors have fewer recurrent infarctions, a lower incidence of severe congestive heart failure, and a reduced incidence of total cardiovascular death and sudden cardiac death. | 1017-1269 | 1,017 | 1,269 | @OBJECT$ @PREDICAT$ class I-IV @SUBJECT$ treated with ACE inhibitors have fewer recurrent infarctions, a lower incidence of severe congestive heart failure, and a reduced incidence of total cardiovascular death and sudden cardiac death. |
Fact | preserve | 793-819 | 812-819 | T52 | beta-blocker therapy | USES | 793 | 819 | preserve | 812-819 | 812-819 | T40 | therapy | TherapeuticOrPreventiveProcedure | 812 | 819 | preserve | 793-805 | 793-805 | T39 | beta-blocker | PharmacologicSubstance | 793 | 805 | A21 | It appears from the findings of recent studies that the greatest benefit from beta-blocker therapy is achieved in patients who are more than 60 years of age and in patients at moderate or high risk for reinfarction and death (eg, patients with LV dysfunction or arrhythmias or both). | 709-1016 | 709 | 1,016 | It appears from the findings of recent studies that the greatest benefit from @OBJECT$ @PREDICAT$ @SUBJECT$ is achieved in patients who are more than 60 years of age and in patients at moderate or high risk for reinfarction and death (eg, patients with LV dysfunction or arrhythmias or both). |
Fact | preserve | 1628-1632 | 1628-1632 | T105 | with | USES | 1,628 | 1,632 | preserve | 1620-1627 | 1620-1627 | T97 | therapy | TherapeuticOrPreventiveProcedure | 1,620 | 1,627 | preserve | 1641-1653 | 1641-1653 | T98 | beta-blocker | PharmacologicSubstance | 1,641 | 1,653 | A22 | There is also growing evidence that concomitant therapy with a beta-blocker and an ACE inhibitor may reduce mortality rates beyond that observed with ACE inhibitors alone in survivors of MI who have LV dysfunction. | 1572-1798 | 1,572 | 1,798 | There is also growing evidence that concomitant @SUBJECT$ @PREDICAT$ a @OBJECT$ and an ACE inhibitor may reduce mortality rates beyond that observed with ACE inhibitors alone in survivors of MI who have LV dysfunction. |
Fact | preserve | 1494-1498 | 1494-1498 | T92 | have | PROCESS_OF | 1,494 | 1,498 | preserve | 1526-1538 | 1526-1538 | T88 | hypertension | DiseaseOrSyndrome | 1,526 | 1,538 | preserve | 1448-1456 | 1448-1456 | T84 | patients | PatientOrDisabledGroup | 1,448 | 1,456 | A23 | In addition to the studies completed in patients with MI, there are ongoing studies evaluating whether or not ACE inhibitors can reduce myocardial ischemic events in patients without a prior infarction who have coronary artery disease or hypertension and preserved LV function. | 1270-1571 | 1,270 | 1,571 | In addition to the studies completed in patients with MI, there are ongoing studies evaluating whether or not ACE inhibitors can reduce myocardial ischemic events in @OBJECT$ without a prior infarction who @PREDICAT$ coronary artery disease or @SUBJECT$ and preserved LV function. |
Counterfact | preserve | 766-777 | 774-777 | T47 | smoking men | PROCESS_OF | 766 | 777 | preserve | 766-773 | 766-773 | T45 | smoking | IndividualBehavior | 766 | 773 | preserve | 774-777 | 774-777 | T46 | men | PopulationGroup | 774 | 777 | A1 | All subjects were non-smoking men. | 744-778 | 744 | 778 | All subjects were non- @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 1486-1488 | 1486-1488 | T83 | in | COEXISTS_WITH | 1,486 | 1,488 | preserve | 1458-1485 | 1473-1485 | T72 | chronic airway inflammation | PathologicFunction | 1,458 | 1,485 | preserve | 1495-1505 | 1495-1505 | T73 | bronchitis | DiseaseOrSyndrome | 1,495 | 1,505 | A3 | These results indicate that cough sensitivity is potentiated by chronic airway inflammation in bronchitis but not in asthma, and suggest that cough sensitivity and bronchial responsiveness may be independently potentiated by different mechanisms resulting from chronic airway inflammation. | 1388-1701 | 1,388 | 1,701 | These results indicate that cough sensitivity is potentiated by @SUBJECT$ @PREDICAT$ @OBJECT$ but not in asthma, and suggest that cough sensitivity and bronchial responsiveness may be independently potentiated by different mechanisms resulting from chronic airway inflammation. |
Fact | preserve | 97-99 | 97-99 | T11 | in | TREATS | 97 | 99 | preserve | 84-96 | 84-96 | T7 | methacholine | IndicatorReagentOrDiagnosticAid | 84 | 96 | preserve | 100-109 | 100-109 | T8 | asthmatic | DiseaseOrSyndrome | 100 | 109 | A4 | Airway cough sensitivity to inhaled capsaicin and bronchial responsiveness to methacholine in asthmatic and bronchitic subjects. | 0-134 | 0 | 134 | Airway cough sensitivity to inhaled capsaicin and bronchial responsiveness to @SUBJECT$ @PREDICAT$ @OBJECT$ and bronchitic subjects. |
Fact | preserve | 13-24 | 13-24 | T10 | sensitivity | AFFECTS | 13 | 24 | preserve | 36-45 | 36-45 | T4 | capsaicin | Lipid | 36 | 45 | preserve | 7-12 | 7-12 | T1 | cough | SignOrSymptom | 7 | 12 | A5 | Airway cough sensitivity to inhaled capsaicin and bronchial responsiveness to methacholine in asthmatic and bronchitic subjects. | 0-134 | 0 | 134 | Airway @OBJECT$ @PREDICAT$ to inhaled @SUBJECT$ and bronchial responsiveness to methacholine in asthmatic and bronchitic subjects. |
Fact | preserve | 390-397 | 390-397 | T36 | treated | TREATS | 390 | 397 | preserve | 429-436 | 429-436 | T30 | placebo | MedicalDevice | 429 | 436 | preserve | 352-378 | 369-378 | T28 | impaired glucose tolerance | Finding | 352 | 378 | A1 | METHODS: Nineteen obese patients with impaired glucose tolerance (IGT) were treated with either metformin or placebo in a randomized, double-blind, placebo-controlled, cross-over study. | 308-511 | 308 | 511 | METHODS: Nineteen obese patients with @OBJECT$ (IGT) were @PREDICAT$ with either metformin or @SUBJECT$ in a randomized, double-blind, placebo-controlled, cross-over study. |
Fact | preserve | 390-397 | 390-397 | T36 | treated | TREATS | 390 | 397 | preserve | 416-425 | 416-425 | T29 | metformin | OrganicChemical | 416 | 425 | preserve | 352-378 | 369-378 | T28 | impaired glucose tolerance | Finding | 352 | 378 | A2 | METHODS: Nineteen obese patients with impaired glucose tolerance (IGT) were treated with either metformin or placebo in a randomized, double-blind, placebo-controlled, cross-over study. | 308-511 | 308 | 511 | METHODS: Nineteen obese patients with @OBJECT$ (IGT) were @PREDICAT$ with either @SUBJECT$ or placebo in a randomized, double-blind, placebo-controlled, cross-over study. |
Fact | preserve | 332-346 | 338-346 | T34 | obese patients | PROCESS_OF | 332 | 346 | preserve | 332-337 | 332-337 | T26 | obese | DiseaseOrSyndrome | 332 | 337 | preserve | 338-346 | 338-346 | T27 | patients | PatientOrDisabledGroup | 338 | 346 | A3 | METHODS: Nineteen obese patients with impaired glucose tolerance (IGT) were treated with either metformin or placebo in a randomized, double-blind, placebo-controlled, cross-over study. | 308-511 | 308 | 511 | METHODS: Nineteen @SUBJECT$ @PREDICAT$ @OBJECT$ with impaired glucose tolerance (IGT) were treated with either metformin or placebo in a randomized, double-blind, placebo-controlled, cross-over study. |
Fact | preserve | 347-351 | 347-351 | T35 | with | PROCESS_OF | 347 | 351 | preserve | 352-378 | 369-378 | T28 | impaired glucose tolerance | Finding | 352 | 378 | preserve | 338-346 | 338-346 | T27 | patients | PatientOrDisabledGroup | 338 | 346 | A5 | METHODS: Nineteen obese patients with impaired glucose tolerance (IGT) were treated with either metformin or placebo in a randomized, double-blind, placebo-controlled, cross-over study. | 308-511 | 308 | 511 | METHODS: Nineteen obese @OBJECT$ @PREDICAT$ @SUBJECT$ (IGT) were treated with either metformin or placebo in a randomized, double-blind, placebo-controlled, cross-over study. |
Fact | preserve | 120-124 | 120-124 | T14 | with | PROCESS_OF | 120 | 124 | preserve | 125-151 | 142-151 | T10 | impaired glucose tolerance | Finding | 125 | 151 | preserve | 111-119 | 111-119 | T9 | patients | PatientOrDisabledGroup | 111 | 119 | A6 | Metformin treatment leads to an increase in basal, but not insulin-stimulated, glucose disposal in obese patients with impaired glucose tolerance. | 0-152 | 0 | 152 | Metformin treatment leads to an increase in basal, but not insulin-stimulated, glucose disposal in obese @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 390-397 | 390-397 | T36 | treated | TREATS | 390 | 397 | preserve | 429-436 | 429-436 | T30 | placebo | MedicalDevice | 429 | 436 | preserve | 338-346 | 338-346 | T27 | patients | PatientOrDisabledGroup | 338 | 346 | A7 | METHODS: Nineteen obese patients with impaired glucose tolerance (IGT) were treated with either metformin or placebo in a randomized, double-blind, placebo-controlled, cross-over study. | 308-511 | 308 | 511 | METHODS: Nineteen obese @OBJECT$ with impaired glucose tolerance (IGT) were @PREDICAT$ with either metformin or @SUBJECT$ in a randomized, double-blind, placebo-controlled, cross-over study. |
Fact | preserve | 1464-1478 | 1464-1478 | T100 | administration | ADMINISTERED_TO | 1,464 | 1,478 | preserve | 1454-1463 | 1454-1463 | T91 | metformin | OrganicChemical | 1,454 | 1,463 | preserve | 1482-1490 | 1482-1490 | T92 | patients | PatientOrDisabledGroup | 1,482 | 1,490 | A8 | CONCLUSIONS: These results indicate that metformin administration to patients with IGT is associated with enhanced glucose disposal at baseline insulin concentrations and a fall in blood pressure. | 1406-1622 | 1,406 | 1,622 | CONCLUSIONS: These results indicate that @SUBJECT$ @PREDICAT$ to @OBJECT$ with IGT is associated with enhanced glucose disposal at baseline insulin concentrations and a fall in blood pressure. |
Fact | preserve | 212-231 | 222-231 | T24 | metformin treatment | USES | 212 | 231 | preserve | 222-231 | 222-231 | T20 | treatment | TherapeuticOrPreventiveProcedure | 222 | 231 | preserve | 212-221 | 212-221 | T19 | metformin | OrganicChemical | 212 | 221 | A9 | AIMS: This study was initiated to test the hypothesis that metformin treatment leads to enhanced glucose disposal at ambient insulin concentrations. | 153-307 | 153 | 307 | AIMS: This study was initiated to test the hypothesis that @OBJECT$ @PREDICAT$ @SUBJECT$ leads to enhanced glucose disposal at ambient insulin concentrations. |
Fact | preserve | 105-119 | 111-119 | T12 | obese patients | PROCESS_OF | 105 | 119 | preserve | 105-110 | 105-110 | T8 | obese | DiseaseOrSyndrome | 105 | 110 | preserve | 111-119 | 111-119 | T9 | patients | PatientOrDisabledGroup | 111 | 119 | A11 | Metformin treatment leads to an increase in basal, but not insulin-stimulated, glucose disposal in obese patients with impaired glucose tolerance. | 0-152 | 0 | 152 | Metformin treatment leads to an increase in basal, but not insulin-stimulated, glucose disposal in @SUBJECT$ @PREDICAT$ @OBJECT$ with impaired glucose tolerance. |
Fact | preserve | 1724-1743 | 1734-1743 | T110 | metformin treatment | USES | 1,724 | 1,743 | preserve | 1734-1743 | 1734-1743 | T106 | treatment | TherapeuticOrPreventiveProcedure | 1,734 | 1,743 | preserve | 1724-1733 | 1724-1733 | T105 | metformin | OrganicChemical | 1,724 | 1,733 | A12 | In contrast, neither glucose oxidation nor glucose disposal were increased in association with metformin treatment under conditions of physiological hyperinsulinaemia. | 1623-1802 | 1,623 | 1,802 | In contrast, neither glucose oxidation nor glucose disposal were increased in association with @OBJECT$ @PREDICAT$ @SUBJECT$ under conditions of physiological hyperinsulinaemia. |
Fact | preserve | 0-19 | 10-19 | T11 | Metformin treatment | USES | 0 | 19 | preserve | 10-19 | 10-19 | T2 | treatment | TherapeuticOrPreventiveProcedure | 10 | 19 | preserve | 0-9 | 0-9 | T1 | Metformin | OrganicChemical | 0 | 9 | A15 | Metformin treatment leads to an increase in basal, but not insulin-stimulated, glucose disposal in obese patients with impaired glucose tolerance. | 0-152 | 0 | 152 | @OBJECT$ @PREDICAT$ @SUBJECT$ leads to an increase in basal, but not insulin-stimulated, glucose disposal in obese patients with impaired glucose tolerance. |
Fact | preserve | 390-397 | 390-397 | T36 | treated | TREATS | 390 | 397 | preserve | 416-425 | 416-425 | T29 | metformin | OrganicChemical | 416 | 425 | preserve | 338-346 | 338-346 | T27 | patients | PatientOrDisabledGroup | 338 | 346 | A17 | METHODS: Nineteen obese patients with impaired glucose tolerance (IGT) were treated with either metformin or placebo in a randomized, double-blind, placebo-controlled, cross-over study. | 308-511 | 308 | 511 | METHODS: Nineteen obese @OBJECT$ with impaired glucose tolerance (IGT) were @PREDICAT$ with either @SUBJECT$ or placebo in a randomized, double-blind, placebo-controlled, cross-over study. |
Fact | preserve | 1491-1495 | 1491-1495 | T101 | with | PROCESS_OF | 1,491 | 1,495 | preserve | 1496-1499 | 1496-1499 | T93 | IGT | Finding | 1,496 | 1,499 | preserve | 1482-1490 | 1482-1490 | T92 | patients | PatientOrDisabledGroup | 1,482 | 1,490 | A19 | CONCLUSIONS: These results indicate that metformin administration to patients with IGT is associated with enhanced glucose disposal at baseline insulin concentrations and a fall in blood pressure. | 1406-1622 | 1,406 | 1,622 | CONCLUSIONS: These results indicate that metformin administration to @OBJECT$ @PREDICAT$ @SUBJECT$ is associated with enhanced glucose disposal at baseline insulin concentrations and a fall in blood pressure. |
Possible | preserve | 1678-1685 | 1678-1685 | T104 | benefit | TREATS | 1,678 | 1,685 | preserve | 1696-1706 | 1696-1706 | T103 | pranlukast | OrganicChemical | 1,696 | 1,706 | preserve | 1591-1601 | 1591-1601 | T98 | asthmatics | DiseaseOrSyndrome | 1,591 | 1,601 | A2 | Severe asthmatics (FEV1.0 < 80%) who deteriorate after reduction of inhaled steroid may benefit most from pranlukast. | 1584-1707 | 1,584 | 1,707 | Severe @OBJECT$ (FEV1.0 < 80%) who deteriorate after reduction of inhaled steroid may @PREDICAT$ most from @SUBJECT$ . |
Fact | preserve | 251-267 | 257-267 | T20 | adult asthmatics | PROCESS_OF | 251 | 267 | preserve | 257-267 | 257-267 | T18 | asthmatics | DiseaseOrSyndrome | 257 | 267 | preserve | 251-256 | 251-256 | T17 | adult | AgeGroup | 251 | 256 | A3 | We undertook a community based case-control study to measure the effect of pranlukast on the reduction of inhaled steroid in adult asthmatics. | 120-268 | 120 | 268 | We undertook a community based case-control study to measure the effect of pranlukast on the reduction of inhaled steroid in @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 655-662 | 655-662 | T48 | receive | ADMINISTERED_TO | 655 | 662 | preserve | 670-680 | 670-680 | T43 | pranlukast | OrganicChemical | 670 | 680 | preserve | 616-624 | 616-624 | T42 | Patients | PatientOrDisabledGroup | 616 | 624 | A5 | Patients were then randomized to receive either pranlukast with 400 microgram of BDP or 400 microgram alone for 8 weeks. | 616-748 | 616 | 748 | @OBJECT$ were then randomized to @PREDICAT$ either @SUBJECT$ with 400 microgram of BDP or 400 microgram alone for 8 weeks. |
Fact | preserve | 101-117 | 107-117 | T9 | adult asthmatics | PROCESS_OF | 101 | 117 | preserve | 107-117 | 107-117 | T8 | asthmatics | DiseaseOrSyndrome | 107 | 117 | preserve | 101-106 | 101-106 | T7 | adult | AgeGroup | 101 | 106 | A7 | [Pranlukast allows reduction of inhaled steroid dose without deterioration in lung function in adult asthmatics]. | 0-119 | 0 | 119 | [Pranlukast allows reduction of inhaled steroid dose without deterioration in lung function in @OBJECT$ @PREDICAT$ @SUBJECT$ ]. |
Fact | preserve | 185-191 | 185-191 | T19 | effect | INTERACTS_WITH | 185 | 191 | preserve | 240-247 | 240-247 | T16 | steroid | Steroid | 240 | 247 | preserve | 201-211 | 201-211 | T14 | pranlukast | OrganicChemical | 201 | 211 | A8 | We undertook a community based case-control study to measure the effect of pranlukast on the reduction of inhaled steroid in adult asthmatics. | 120-268 | 120 | 268 | We undertook a community based case-control study to measure the @PREDICAT$ of @OBJECT$ on the reduction of inhaled @SUBJECT$ in adult asthmatics. |
Fact | preserve | 625-629 | 625-629 | T38 | with | USES | 625 | 629 | preserve | 617-624 | 617-624 | T34 | therapy | TherapeuticOrPreventiveProcedure | 617 | 624 | preserve | 636-676 | 666-676 | T35 | angiotensin-converting enzyme inhibitors | PharmacologicSubstance | 636 | 676 | A1 | Long-term therapy with angiotensin-converting enzyme inhibitors should be continued in patients with systolic dysfunction. | 607-741 | 607 | 741 | Long-term @SUBJECT$ @PREDICAT$ @OBJECT$ should be continued in patients with systolic dysfunction. |
Fact | preserve | 709-713 | 709-713 | T39 | with | PROCESS_OF | 709 | 713 | preserve | 720-740 | 729-740 | T37 | systolic dysfunction | PathologicFunction | 720 | 740 | preserve | 700-708 | 700-708 | T36 | patients | PatientOrDisabledGroup | 700 | 708 | A2 | Long-term therapy with angiotensin-converting enzyme inhibitors should be continued in patients with systolic dysfunction. | 607-741 | 607 | 741 | Long-term therapy with angiotensin-converting enzyme inhibitors should be continued in @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 437-441 | 437-441 | T29 | with | PROCESS_OF | 437 | 441 | preserve | 442-480 | 473-480 | T23 | atherosclerotic cardiovascular disease | DiseaseOrSyndrome | 442 | 480 | preserve | 428-436 | 428-436 | T22 | patients | PatientOrDisabledGroup | 428 | 436 | A3 | All patients with atherosclerotic cardiovascular disease should be considered for lipid lowering therapy, antiplatelet agents, beta-blockers, and control of hypertension. | 424-606 | 424 | 606 | All @OBJECT$ @PREDICAT$ @SUBJECT$ should be considered for lipid lowering therapy, antiplatelet agents, beta-blockers, and control of hypertension. |
Fact | preserve | 178-182 | 178-182 | T12 | with | PROCESS_OF | 178 | 182 | preserve | 189-205 | 198-205 | T10 | coronary disease | DiseaseOrSyndrome | 189 | 205 | preserve | 169-177 | 169-177 | T8 | patients | PatientOrDisabledGroup | 169 | 177 | A6 | Compelling evidence from clinical trials confirms the benefits of secondary prevention for patients with known coronary disease. | 72-206 | 72 | 206 | Compelling evidence from clinical trials confirms the benefits of secondary prevention for @OBJECT$ @PREDICAT$ known @SUBJECT$ . |
Fact | preserve | 165-168 | 165-168 | T11 | for | TREATS | 165 | 168 | preserve | 138-164 | 154-164 | T7 | secondary prevention | TherapeuticOrPreventiveProcedure | 138 | 164 | preserve | 169-177 | 169-177 | T8 | patients | PatientOrDisabledGroup | 169 | 177 | A7 | Compelling evidence from clinical trials confirms the benefits of secondary prevention for patients with known coronary disease. | 72-206 | 72 | 206 | Compelling evidence from clinical trials confirms the benefits of @SUBJECT$ @PREDICAT$ @OBJECT$ with known coronary disease. |
Fact | preserve | 165-168 | 165-168 | T11 | for | TREATS | 165 | 168 | preserve | 138-164 | 154-164 | T7 | secondary prevention | TherapeuticOrPreventiveProcedure | 138 | 164 | preserve | 189-205 | 198-205 | T10 | coronary disease | DiseaseOrSyndrome | 189 | 205 | A8 | Compelling evidence from clinical trials confirms the benefits of secondary prevention for patients with known coronary disease. | 72-206 | 72 | 206 | Compelling evidence from clinical trials confirms the benefits of @SUBJECT$ @PREDICAT$ patients with known @OBJECT$ . |
Possible | preserve | 1930-1937 | 1930-1937 | T128 | promote | PREDISPOSES | 1,930 | 1,937 | preserve | 1810-1816 | 1810-1816 | T112 | leptin | AminoAcidPeptideOrProtein | 1,810 | 1,816 | preserve | 1938-1943 | 1938-1943 | T121 | tumor | NeoplasticProcess | 1,938 | 1,943 | A1 | The elevated levels of aromatase activity may contribute to increase circulating estrogen levels in certain obese women and suggest that elevated leptin concentrations in obese women may cause locally elevated estrogen concentrations in the breast and thereby promote tumor formation. | 1652-1960 | 1,652 | 1,960 | The elevated levels of aromatase activity may contribute to increase circulating estrogen levels in certain obese women and suggest that elevated @SUBJECT$ concentrations in obese women may cause locally elevated estrogen concentrations in the breast and thereby @PREDICAT$ @OBJECT$ formation. |
Fact | preserve | 1832-1834 | 1832-1834 | T126 | in | LOCATION_OF | 1,832 | 1,834 | preserve | 1841-1846 | 1841-1846 | T115 | women | PopulationGroup | 1,841 | 1,846 | preserve | 1810-1816 | 1810-1816 | T112 | leptin | AminoAcidPeptideOrProtein | 1,810 | 1,816 | A2 | The elevated levels of aromatase activity may contribute to increase circulating estrogen levels in certain obese women and suggest that elevated leptin concentrations in obese women may cause locally elevated estrogen concentrations in the breast and thereby promote tumor formation. | 1652-1960 | 1,652 | 1,960 | The elevated levels of aromatase activity may contribute to increase circulating estrogen levels in certain obese women and suggest that elevated @OBJECT$ concentrations @PREDICAT$ obese @SUBJECT$ may cause locally elevated estrogen concentrations in the breast and thereby promote tumor formation. |
Counterfact | preserve | 1143-1149 | 1143-1149 | T74 | effect | AFFECTS | 1,143 | 1,149 | preserve | 1039-1045 | 1039-1045 | T65 | Leptin | AminoAcidPeptideOrProtein | 1,039 | 1,045 | preserve | 1153-1171 | 1163-1171 | T73 | aromatase activity | MolecularFunction | 1,153 | 1,171 | A3 | Leptin concentrations in the physiological range of normal weight or thin women (10 ng/ml) had no effect on aromatase activity. | 1039-1172 | 1,039 | 1,172 | @SUBJECT$ concentrations in the physiological range of normal weight or thin women (10 ng/ml) had no @PREDICAT$ on @OBJECT$ . |
Fact | preserve | 1333-1335 | 1333-1335 | T86 | in | ASSOCIATED_WITH | 1,333 | 1,335 | preserve | 1251-1256 | 1251-1256 | T81 | obese | DiseaseOrSyndrome | 1,251 | 1,256 | preserve | 1336-1354 | 1346-1354 | T85 | aromatase activity | MolecularFunction | 1,336 | 1,354 | A4 | In 2 of 8 abdominal fat cultures and 1 of 2 breast fat cultures, a high obese concentration of leptin (100 ng/ml) stimulated a significant increase in aromatase activity. | 1173-1355 | 1,173 | 1,355 | In 2 of 8 abdominal fat cultures and 1 of 2 breast fat cultures, a high @SUBJECT$ concentration of leptin (100 ng/ml) stimulated a significant increase @PREDICAT$ @OBJECT$ . |
Fact | preserve | 326-328 | 326-328 | T32 | in | LOCATION_OF | 326 | 328 | preserve | 337-356 | 351-356 | T24 | stromal cells | Cell | 337 | 356 | preserve | 302-311 | 302-311 | T22 | aromatase | AminoAcidPeptideOrProtein | 302 | 311 | A6 | The aromatase gene promoter in adipose stromal cells contains a functional STAT binding region, leading to the hypothesis that leptin may regulate aromatase activity in fat tissue. | 298-490 | 298 | 490 | The @OBJECT$ gene promoter @PREDICAT$ adipose @SUBJECT$ contains a functional STAT binding region, leading to the hypothesis that leptin may regulate aromatase activity in fat tissue. |
Fact | preserve | 756-768 | 762-768 | T52 | human leptin | PART_OF | 756 | 768 | preserve | 762-768 | 762-768 | T51 | leptin | AminoAcidPeptideOrProtein | 762 | 768 | preserve | 756-761 | 756-761 | T50 | human | Human | 756 | 761 | A7 | MATERIALS AND METHODS: The cells were treated for three days with increasing concentrations of recombinant human leptin. | 643-769 | 643 | 769 | MATERIALS AND METHODS: The cells were treated for three days with increasing concentrations of recombinant @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 1835-1846 | 1841-1846 | T125 | obese women | PROCESS_OF | 1,835 | 1,846 | preserve | 1835-1840 | 1835-1840 | T114 | obese | DiseaseOrSyndrome | 1,835 | 1,840 | preserve | 1841-1846 | 1841-1846 | T115 | women | PopulationGroup | 1,841 | 1,846 | A10 | The elevated levels of aromatase activity may contribute to increase circulating estrogen levels in certain obese women and suggest that elevated leptin concentrations in obese women may cause locally elevated estrogen concentrations in the breast and thereby promote tumor formation. | 1652-1960 | 1,652 | 1,960 | The elevated levels of aromatase activity may contribute to increase circulating estrogen levels in certain obese women and suggest that elevated leptin concentrations in @SUBJECT$ @PREDICAT$ @OBJECT$ may cause locally elevated estrogen concentrations in the breast and thereby promote tumor formation. |
Uncommitted | preserve | 7-17 | 7-17 | T7 | regulation | AFFECTS | 7 | 17 | preserve | 0-6 | 0-6 | T1 | Leptin | AminoAcidPeptideOrProtein | 0 | 6 | preserve | 21-39 | 31-39 | T3 | aromatase activity | MolecularFunction | 21 | 39 | A11 | Leptin regulation of aromatase activity in adipose stromal cells from regularly cycling women. | 0-100 | 0 | 100 | @SUBJECT$ @PREDICAT$ of @OBJECT$ in adipose stromal cells from regularly cycling women. |
Fact | preserve | 277-283 | 277-283 | T21 | within | LOCATION_OF | 277 | 283 | preserve | 284-296 | 291-296 | T20 | target cells | Cell | 284 | 296 | preserve | 257-276 | 268-276 | T19 | STAT proteins | AminoAcidPeptideOrProtein | 257 | 276 | A13 | Leptin causes the activation of STAT proteins within target cells. | 225-297 | 225 | 297 | Leptin causes the activation of @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 1766-1777 | 1772-1777 | T123 | obese women | PROCESS_OF | 1,766 | 1,777 | preserve | 1766-1771 | 1766-1771 | T109 | obese | DiseaseOrSyndrome | 1,766 | 1,771 | preserve | 1772-1777 | 1772-1777 | T110 | women | PopulationGroup | 1,772 | 1,777 | A14 | The elevated levels of aromatase activity may contribute to increase circulating estrogen levels in certain obese women and suggest that elevated leptin concentrations in obese women may cause locally elevated estrogen concentrations in the breast and thereby promote tumor formation. | 1652-1960 | 1,652 | 1,960 | The elevated levels of aromatase activity may contribute to increase circulating estrogen levels in certain @SUBJECT$ @PREDICAT$ @OBJECT$ and suggest that elevated leptin concentrations in obese women may cause locally elevated estrogen concentrations in the breast and thereby promote tumor formation. |
Possible | preserve | 448-456 | 448-456 | T33 | regulate | AFFECTS | 448 | 456 | preserve | 437-443 | 437-443 | T29 | leptin | AminoAcidPeptideOrProtein | 437 | 443 | preserve | 457-475 | 467-475 | T30 | aromatase activity | MolecularFunction | 457 | 475 | A15 | The aromatase gene promoter in adipose stromal cells contains a functional STAT binding region, leading to the hypothesis that leptin may regulate aromatase activity in fat tissue. | 298-490 | 298 | 490 | The aromatase gene promoter in adipose stromal cells contains a functional STAT binding region, leading to the hypothesis that @SUBJECT$ may @PREDICAT$ @OBJECT$ in fat tissue. |
Fact | preserve | 1467-1557 | 1524-1534 | T68 | occupational asthma are directly applicable to the evaluation of diisocyanate asthma | ISA | 1,467 | 1,557 | preserve | 1467-1486 | 1480-1486 | T66 | occupational asthma | DiseaseOrSyndrome | 1,467 | 1,486 | preserve | 1551-1557 | 1551-1557 | T67 | asthma | DiseaseOrSyndrome | 1,551 | 1,557 | A1 | CONCLUSIONS: Published diagnostic guidelines for occupational asthma are directly applicable to the evaluation of diisocyanate asthma. | 1418-1558 | 1,418 | 1,558 | CONCLUSIONS: Published diagnostic guidelines for @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 364-373 | 364-373 | T27 | diagnosis | DIAGNOSES | 364 | 373 | preserve | 507-524 | 519-524 | T24 | immunologic tests | DiagnosticProcedure | 507 | 524 | preserve | 390-396 | 390-396 | T19 | asthma | DiseaseOrSyndrome | 390 | 396 | A2 | The accurate diagnosis of diisocyanate asthma requires a systematic approach that combines information obtained from the occupational history, immunologic tests and physiologic studies. | 351-549 | 351 | 549 | The accurate @PREDICAT$ of diisocyanate @OBJECT$ requires a systematic approach that combines information obtained from the occupational history, @SUBJECT$ and physiologic studies. |